Inclusion Criteria:

- older than 18 years,

- male or female,

- diagnosis of secondary liver cancer or cholangiocarcinoma based on positive biopsy or
noninvasive criteria,

- presence of at least one lesion untreatable by surgical resection or ablation for
microwave or radio frequency,

- the target nodule must have a diameter of ≤ 5 cm

- ECOG score(Eastern Cooperative Oncology Group) 0,

- ASA score (American Society of Anesthesiologists) ≤ 3,

- prothrombin time ratio >50%

- platelet count >50x10^9/l,

- patient's ability to discontinue anticoagulant and antiplatelet therapy for seven
days before and seven days after surgery with NanoKnife™,

- ability to understand and willingness to sign the written informed consent form
(ICF),

- life expectancy of at least 3 months.

Exclusion Criteria:

- presence of more than 5 liver lesions,

- previous treatment of the target nodule,

- patient received systemic chemotherapy within 30 days of treatment with the IRE
NanoKnife™,

- heart failure, coronary artery disease or arrhythmia in progress, active implantable
devices (eg pacemaker),

- pregnant women or women of childbearing potential not using an acceptable method of
contraception,

- patient undergoing treatment with an investigational drug within 30 days of treatment
with the IRE NanoKnife™,

- in the opinion of the researcher, anyone who can not follow the calendar of visits
and assessments of the Protocol.